| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 44.33B | $ 41.95B | $ 40.11B | $ 43.65B | $ 43.08B |
| Gross Profit | $ 24.61B | $ 21.32B | $ 20.04B | $ 22.32B | $ 23.21B |
| Operating Income | $ 8.05B | $ 6.83B | $ 6.43B | $ 8.36B | $ 9.20B |
| EBITDA | $ 11.55B | $ 10.83B | $ 10.61B | $ 11.89B | $ 12.16B |
| Net Income | $ 6.52B | $ 13.40B | $ 5.72B | $ 6.93B | $ 7.07B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 8.94B | $ 7.97B | $ 7.28B | $ 10.17B | $ 10.25B |
| Total Assets | $ 86.71B | $ 81.41B | $ 73.21B | $ 74.44B | $ 75.20B |
| Total Debt | $ 15.07B | $ 15.28B | $ 15.87B | $ 17.95B | $ 19.25B |
| Net Debt | $ 6.54B | $ 7.66B | $ 8.98B | $ 8.06B | $ 9.45B |
| Total Liabilities | $ 33.94B | $ 33.51B | $ 34.39B | $ 37.53B | $ 39.17B |
| Stockholders' Equity | $ 52.13B | $ 47.66B | $ 38.60B | $ 36.69B | $ 35.80B |
| Cash Flow | |||||
| Free Cash Flow | $ 7.39B | $ 6.35B | $ 5.06B | $ 7.80B | $ 8.65B |
| Operating Cash Flow | $ 9.57B | $ 8.56B | $ 7.26B | $ 9.58B | $ 10.53B |
| Investing Cash Flow | $ -2.42B | $ -2.34B | $ -3.13B | $ -1.74B | $ -2.01B |
| Financing Cash Flow | $ -6.31B | $ -5.40B | $ -7.09B | $ -7.64B | $ -5.49B |
Abbott Laboratories (CH:ABT)
:ABT
